Abstract
The search for the cause of cancer has led to five successive theories involving viruses, oncogenes, tumor suppressor genes, somatic mutation cascade and inflammation. The latter, without discarding the former theories, is now the prevailing paradigm recognizing that neoplastic cells require participation of the microenvironment for tumor progression. Inflammatory reactions are dependent on an overabundance of immune responses which are both in favor and against tumor development. This homeostatic immunological behavior has led to the concept of tumor immunoediting in an attempt to elucidate why tumors grow. This review is a non-exhaustive description of the different experimental highlights which have led to our present knowledge of cancer. During its 47 years of existence, our laboratory has contributed extensively to the experimental development of onco-immunology, so that our results are described within the background of international discoveries. As for cancer therapy, the many attempts made, both at the experimental and clinical levels, have been mainly frustrating and yet, as oncologists, we are always ready to try again.
Keywords: experimental oncology, retrovirus, mmtv, oncogene, anti-oncogene, tumor immunoediting
Current Cancer Therapy Reviews
Title: Experimental Onco-Immunology Revisited
Volume: 1 Issue: 3
Author(s): Christiane D. Pasqualini, Raul A. Ruggiero, Oscar D. Bustuoabad, Irene Nepomnaschy and Isabel Piazzon
Affiliation:
Keywords: experimental oncology, retrovirus, mmtv, oncogene, anti-oncogene, tumor immunoediting
Abstract: The search for the cause of cancer has led to five successive theories involving viruses, oncogenes, tumor suppressor genes, somatic mutation cascade and inflammation. The latter, without discarding the former theories, is now the prevailing paradigm recognizing that neoplastic cells require participation of the microenvironment for tumor progression. Inflammatory reactions are dependent on an overabundance of immune responses which are both in favor and against tumor development. This homeostatic immunological behavior has led to the concept of tumor immunoediting in an attempt to elucidate why tumors grow. This review is a non-exhaustive description of the different experimental highlights which have led to our present knowledge of cancer. During its 47 years of existence, our laboratory has contributed extensively to the experimental development of onco-immunology, so that our results are described within the background of international discoveries. As for cancer therapy, the many attempts made, both at the experimental and clinical levels, have been mainly frustrating and yet, as oncologists, we are always ready to try again.
Export Options
About this article
Cite this article as:
Pasqualini D. Christiane, Ruggiero A. Raul, Bustuoabad D. Oscar, Nepomnaschy Irene and Piazzon Isabel, Experimental Onco-Immunology Revisited, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574225
DOI https://dx.doi.org/10.2174/157339405774574225 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets Targeting Basal-Like Breast Cancers
Current Drug Targets Defining the Role of Integrin αvβ6 in Cancer
Current Drug Targets Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Synthetic Nanocarriers for Intracellular Protein Delivery
Current Drug Metabolism Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Structural Modification of Sylibin to Derivatives of Sylibin/Hydnocarpin D/Silandrin, and Evaluation of their Cytotoxicity against Cancer Cells
Current Topics in Medicinal Chemistry Histopathology, Immunohistochemistry and Molecular Biology of Follicular Epithelium-Derived Pediatric Thyroid Carcinomas
Current Pediatric Reviews Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
Current Cancer Drug Targets Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging Formulation and Characterization of Rutin Loaded Chitosan-alginate Nanoparticles: Antidiabetic and Cytotoxicity Studies
Current Drug Delivery Synthesis and Cytotoxicity of 4-(2-Adamantyl)phenylalkylamines
Letters in Organic Chemistry Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Current Concepts on the Management of Chordoma
Current Drug Therapy